The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1603-1613

  Tiffen, Jessamy C ^a,c   Bailey, Charles G ^a,c   Marshall, Amy D ^a   Metierre, Cynthia ^a   Feng, Yue ^a   Wang, Qian ^a,b   Watson, Sarah L ^a   Holst, Jeff ^b,c   Rasko, John E J ^a,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BORIS; cancer; CTCF; mutation; tumor suppressor; zinc finger

Indexed keywords

BROTHER OF THE REGULATOR OF IMPRINTED SITE PROTEIN; CANCER TESTIS ANTIGEN; TRANSCRIPTION FACTOR CTCF; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BORIS GENE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL PROTECTION; CLONOGENESIS; CONTROLLED STUDY; CTCF GENE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MISSENSE MUTATION; MOUSE; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; ZINC FINGER MOTIF;

BORIS; CANCER; CTCF; MUTATION; TUMOR SUPPRESSOR; ZINC FINGER;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CODON, NONSENSE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICE; MUTATION, MISSENSE; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

EID: 84880295646     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28184     Document Type: Article

References (50)

1. Aulmann S, Bläker H, Penzel R, et al. CTCF gene mutations in invasive ductal breast cancer. Breast Cancer Res Treat 2003; 80: 347-52.
2. Filippova GN, Qi CF, Ulmer JE, et al. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter its DNA-binding specificity. Cancer Res 2002; 62: 48-52.
3. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-9.
4. Torrano V, Chernukhin I, Docquier F, et al. CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. J Biol Chem 2005; 280: 28152-61.
5. Chao W, Huynh KD, Spencer RJ, et al. CTCF, a candidate trans-acting factor for X-inactivation choice. Science 2002; 295: 345-7.
6. Bell AC, West AG, Felsenfeld G,. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 1999; 98: 387-96.
7. Kim TH, Abdullaev ZK, Smith AD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 2007; 128: 1231-45.
8. Moore JM, Rabaia NA, Smith LE, et al. Loss of maternal CTCF Is associated with peri-implantation lethality of Ctcf null embryos. PLoS One 2012; 7: e34915.
9. Rasko JE, Klenova EM, Leon J, et al. Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res 2001; 61: 6002-7.
10. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-37.
11. Soto-Reyes E, Recillas-Targa F,. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 2010; 29: 2217-27.
12. Witcher M, Emerson BM,. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009; 34: 271-84.
13. Lai AY, Fatemi M, Dhasarathy A, et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med 2010; 207: 1939-50.
14. Loukinov DI, Pugacheva E, Vatolin S, et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 2002; 99: 6806-11.
15. Jelinic P, Stehle JC, Shaw P,. The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol 2006; 4: e355.
16. Sleutels F, Soochit W, Bartkuhn M, et al. The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner. Epigenetics Chromatin 2012; 5: 1-21.
17. Kosaka-Suzuki N, Suzuki T, Pugacheva EM, et al. Transcription factor BORIS (brother of the regulator of imprinted sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter. J Biol Chem 2011; 286: 27378-88.
18. Suzuki T, Kosaka-Suzuki N, Shin DM, et al. Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene, BORIS. Mol Cell Biol 2010; 30: 2473-84.
19. de Necochea Campion R, Ghochikyan A, Josephs SF, et al. Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med 2011; 9: 213-23.
20. Smith IM, Glazer CA, Mithani SK, et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS ONE 2009; 4: e4961.
21. Vatolin S, Abdullaev Z, Pack SD, et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65: 7751-62.
22. Hong JA, Kang Y, Abdullaev Z, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65: 7763-74.
23. Woloszynska-Read A, James SR, Song C, et al. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 2010; 10: 6.
24. Kholmanskikh O, Loriot A, Brasseur F, et al. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008; 122: 777-84.
25. Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3 and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res 2011; 17: 4267-76.
26. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
27. Mkrtichyan M, Ghochikyan A, Davtyan H, et al. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol 2011; 270: 188-97.
28. Zhang R, Burke LJ, Rasko JE, et al. Dynamic association of the mammalian insulator protein CTCF with centrosomes and the midbody. Exp Cell Res 2004; 294: 86-93.
29. van de Nobelen S, Rosa-Garrido M, Leers J, et al. CTCF regulates the local epigenetic state of ribosomal DNA repeats. Epigenetics Chromatin 2010; 3: 19.
30. Torrano V, Navascués J, Docquier F, et al. Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation- dependent mechanism. J Cell Sci 2006; 119: 1746-59.
31. Jones TA, Ogunkolade BW, Szary J, et al. Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells. PLoS ONE 2011; 6: e22399.
32. Vigna E, Amendola M, Benedicenti F, et al. Efficient Tet-dependent expression of human Factor IX in vivo by a new self-regulating lentiviral vector. Mol Therapy 2005; 11: 763-75.
33. Holst J, Vignali KM, Burton AR, et al. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods 2006; 3: 191-7.
34. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
35. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008; Chapter 10:Unit 10.11.
36. Tiffen JC, Bailey CG, Ng C, et al. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 2010; 9: 299-306.
37. Renda M, Baglivo I, Burgess-Beusse B, et al. Critical DNA binding interactions of the insulator protein CTCF: a small number of zinc fingers mediate strong binding, and a single finger-DNA interaction controls binding at imprinted loci. J Biol Chem 2007; 282: 33336-45.
38. Choo Y, Klug A,. Physical basis of a protein-DNA recognition code. Curr Opin Struct Biol 1997; 7: 117-25.
39. MacPherson MJ, Beatty LG, Zhou W, et al. The CTCF insulator protein is posttranslationally modified by SUMO. Mol Cell Biol 2009; 29: 714-25.
40. Farrar D, Rai S, Chernukhin I, et al. Mutational analysis of the poly(ADP-ribosyl)ation sites of the transcription factor CTCF provides an insight into the mechanism of its regulation by poly(ADP-ribosyl)ation. Mol Cell Biol 2010; 30: 1199-216.
41. El-Kady A, Klenova E,. Regulation of the transcription factor, CTCF, by phosphorylation with protein kinase CK2. FEBS Lett 2005; 579: 1424-34.
42. Pugacheva EM, Suzuki T, Pack SD, et al. The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS ONE 2010; 5: e13872.
43. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
44. Li T, Lu L,. Functional role of CCCTC binding factor (CTCF) in stress-induced apoptosis. Exp Cell Res 2007; 313: 3057-65.
45. Dougherty CJ, Ichim TE, Liu L, et al. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun 2008; 370: 109-12.
46. Docquier F, Farrar D, D'Arcy V, et al. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 2005; 65: 5112-22.
47. Rosa-Garrido M, Ceballos L, Alonso-Lecue P, et al. A cell cycle role for the epigenetic factor CTCF-L/BORIS. PLoS ONE 2012; 7: e39371.
48. Renaud S, Pugacheva EM, Delgado MD, et al. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 2007; 35: 7372-88.
49. Baylin SB, Ohm JE,. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
50. Nguyen P, Cui H, Bisht KS, et al. CTCFL/BORIS is a methylation- independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res 2008; 68: 5546-51.